About
Aqemia is a Paris-based pharmatech company building an AI-driven drug discovery platform that combines quantum-inspired physics and machine learning to generate and prioritise novel drug candidates at scale. Founded in 2019 by quantum physics researcher Maximilien Levesque and former BCG consultant Emmanuelle Martiano, the company aims to design new molecules faster and cheaper than traditional methods. It raised a 60M euro Series A and later a $38M round led by Cathay Innovation in December 2024, bringing total funding past $100 million as it moves toward clinical trials and global expansion, including a London office.
Investors 1
- Cathay Innovation Venture Capital · Paris
Recent news
- AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK 2024-12-10 · Cathay Innovation
- Meet Aqemia, the French company leveraging AI-backed physics tools for drug discovery 2025-05-22 · Euronews